vs
Side-by-side financial comparison of Autolus Therapeutics plc (AUTL) and AMREP CORP. (AXR). Click either name above to swap in a different company.
Autolus Therapeutics plc is the larger business by last-quarter revenue ($21.2M vs $14.6M, roughly 1.5× AMREP CORP.). AMREP CORP. runs the higher net margin — 21.6% vs -373.3%, a 394.9% gap on every dollar of revenue. AMREP CORP. produced more free cash flow last quarter ($5.4M vs $-72.3M).
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company specializing in the development of next-generation engineered chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of hematological malignancies and solid tumors. It operates in the global oncology biotech market, advancing a pipeline of targeted immunotherapy candidates across multiple clinical development stages.
AMREP Corporation is a real estate and media services company based in Princeton, New Jersey, in the United States. It was founded in 1961 as The American Realty and Petroleum Corporation.
AUTL vs AXR — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $21.2M | $14.6M |
| Net Profit | $-79.1M | $3.1M |
| Gross Margin | — | — |
| Operating Margin | -337.9% | 20.6% |
| Net Margin | -373.3% | 21.6% |
| Revenue YoY | — | 93.8% |
| Net Profit YoY | 3.6% | 338.9% |
| EPS (diluted) | $-0.30 | $0.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $14.6M | ||
| Q4 25 | — | $9.4M | ||
| Q3 25 | $21.2M | $17.9M | ||
| Q2 25 | $20.9M | $11.2M | ||
| Q1 25 | $9.0M | $7.5M | ||
| Q4 24 | — | $11.9M | ||
| Q3 24 | $0 | $19.1M | ||
| Q2 24 | $0 | $19.5M |
| Q1 26 | — | $3.1M | ||
| Q4 25 | — | $1.2M | ||
| Q3 25 | $-79.1M | $4.7M | ||
| Q2 25 | $-47.9M | $3.9M | ||
| Q1 25 | $-70.2M | $717.0K | ||
| Q4 24 | — | $4.0M | ||
| Q3 24 | $-82.1M | $4.1M | ||
| Q2 24 | $-58.3M | $4.1M |
| Q1 26 | — | 20.6% | ||
| Q4 25 | — | 11.9% | ||
| Q3 25 | -337.9% | 34.4% | ||
| Q2 25 | -292.6% | 31.7% | ||
| Q1 25 | -726.3% | 5.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 26.1% | ||
| Q2 24 | — | 23.9% |
| Q1 26 | — | 21.6% | ||
| Q4 25 | — | 12.8% | ||
| Q3 25 | -373.3% | 26.3% | ||
| Q2 25 | -229.0% | 34.8% | ||
| Q1 25 | -781.1% | 9.5% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | — | 21.3% | ||
| Q2 24 | — | 21.2% |
| Q1 26 | — | $0.58 | ||
| Q4 25 | — | $0.22 | ||
| Q3 25 | $-0.30 | $0.87 | ||
| Q2 25 | $-0.18 | $0.73 | ||
| Q1 25 | $-0.26 | $0.13 | ||
| Q4 24 | — | $0.75 | ||
| Q3 24 | $-0.31 | $0.76 | ||
| Q2 24 | $-0.22 | $0.77 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $86.1M | $50.0M |
| Total DebtLower is stronger | — | $21.0K |
| Stockholders' EquityBook value | $265.5M | $139.4M |
| Total Assets | $661.9M | $143.9M |
| Debt / EquityLower = less leverage | — | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $50.0M | ||
| Q4 25 | — | $44.6M | ||
| Q3 25 | $86.1M | $48.9M | ||
| Q2 25 | $123.8M | $39.5M | ||
| Q1 25 | $95.8M | $36.9M | ||
| Q4 24 | — | $40.1M | ||
| Q3 24 | $657.1M | $40.4M | ||
| Q2 24 | $705.9M | $29.7M |
| Q1 26 | — | $21.0K | ||
| Q4 25 | — | $23.0K | ||
| Q3 25 | — | $25.0K | ||
| Q2 25 | — | $26.0K | ||
| Q1 25 | — | $29.0K | ||
| Q4 24 | — | $32.0K | ||
| Q3 24 | — | $34.0K | ||
| Q2 24 | — | $35.0K |
| Q1 26 | — | $139.4M | ||
| Q4 25 | — | $136.0M | ||
| Q3 25 | $265.5M | $134.7M | ||
| Q2 25 | $346.5M | $130.0M | ||
| Q1 25 | $371.1M | $126.0M | ||
| Q4 24 | — | $125.1M | ||
| Q3 24 | $477.0M | $122.2M | ||
| Q2 24 | $527.8M | $118.0M |
| Q1 26 | — | $143.9M | ||
| Q4 25 | — | $140.1M | ||
| Q3 25 | $661.9M | $140.7M | ||
| Q2 25 | $721.0M | $133.8M | ||
| Q1 25 | $746.3M | $128.9M | ||
| Q4 24 | — | $129.1M | ||
| Q3 24 | $827.5M | $127.0M | ||
| Q2 24 | $853.6M | $122.8M |
| Q1 26 | — | 0.00× | ||
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-67.9M | $5.4M |
| Free Cash FlowOCF − Capex | $-72.3M | $5.4M |
| FCF MarginFCF / Revenue | -341.2% | 37.0% |
| Capex IntensityCapex / Revenue | 20.8% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.72× |
| TTM Free Cash FlowTrailing 4 quarters | $-322.5M | $20.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.4M | ||
| Q4 25 | — | $-4.3M | ||
| Q3 25 | $-67.9M | $9.5M | ||
| Q2 25 | $-72.8M | $10.2M | ||
| Q1 25 | $-75.6M | $-3.2M | ||
| Q4 24 | — | $-182.0K | ||
| Q3 24 | $-76.7M | $10.7M | ||
| Q2 24 | $-51.1M | $10.7M |
| Q1 26 | — | $5.4M | ||
| Q4 25 | — | $-4.3M | ||
| Q3 25 | $-72.3M | $9.5M | ||
| Q2 25 | $-80.1M | $9.7M | ||
| Q1 25 | $-83.8M | $-3.3M | ||
| Q4 24 | — | $-268.0K | ||
| Q3 24 | $-86.3M | $10.7M | ||
| Q2 24 | $-51.9M | $10.3M |
| Q1 26 | — | 37.0% | ||
| Q4 25 | — | -45.9% | ||
| Q3 25 | -341.2% | 53.2% | ||
| Q2 25 | -382.6% | 86.4% | ||
| Q1 25 | -933.1% | -43.4% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | — | 55.8% | ||
| Q2 24 | — | 52.5% |
| Q1 26 | — | 0.1% | ||
| Q4 25 | — | 0.6% | ||
| Q3 25 | 20.8% | 0.1% | ||
| Q2 25 | 34.8% | 5.2% | ||
| Q1 25 | 91.8% | 0.3% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 2.3% |
| Q1 26 | — | 1.72× | ||
| Q4 25 | — | -3.54× | ||
| Q3 25 | — | 2.03× | ||
| Q2 25 | — | 2.63× | ||
| Q1 25 | — | -4.51× | ||
| Q4 24 | — | -0.05× | ||
| Q3 24 | — | 2.63× | ||
| Q2 24 | — | 2.59× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
